ZENRELIA DIN 02552094
Status: Marketed
Holder: ELANCO CANADA LIMITED
Health Canada record
| Active ingredient(s) | ILUNOCITINIB 8.5 MG |
|---|
| Dosage form | Tablet |
|---|
| Route | Oral |
|---|
| Schedule | PRESCRIPTION |
|---|
| Class | Veterinary |
|---|
| ATC | |
|---|
| Original market date | 03-Jan-2025 |
|---|
| Current status date | 03-Jan-2025 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Elanco Canada Limited — licence 102236, currently licensed, last inspection rating C (2022-08-03).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ILUNOCITINIB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02552108 | ZENRELIA | ELANCO CANADA LIMITED | Tablet | ILUNOCITINIB 15 MG | Marketed |
| 02552051 | ZENRELIA | ELANCO CANADA LIMITED | Tablet | ILUNOCITINIB 4.8 MG | Marketed |
| 02552086 | ZENRELIA | ELANCO CANADA LIMITED | Tablet | ILUNOCITINIB 6.4 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 36356 | 2025-11-12 | Supplement to a New Drug Submission (SNDS) | Labelling update |
| 34079 | 2024-09-25 | New Drug Submission (NDS) | |
Request a quote for ZENRELIA
How to read a Canadian DIN record